Cannabis chocolate trio convicted BBC News Fri, 15 Dec 2006 7:12 AM PST Three people are found guilty of supplying cannabis-laced chocolate bars to multiple sclerosis sufferers for pain relief.

We're Shattered By Shutdown of 'MS Cure' Clinic ; EXCLUSIVE: SUFFERERS' HOPES ARE DASHED RedNova Fri, 15 Dec 2006 2:06 AM PST By Natalie Walker A CONTROVERSIAL clinic which offered hopes of a miracle cure for multiple sclerosis has been shut down. The PMC Clinic in Holland was closed after allegations were made that stem cells used in its treatments were not intended for human use.

Biogen Idec, Elan seek permission to market TYSABRI for Crohn\'s disease in US Sharewatch Fri, 15 Dec 2006 6:26 AM PST The two companies said they have submitted a supplemental biologics licence application (sBLA) for the drug, currently approved as a monotherapy treatment for relapsing forms of multiple sclerosis, to the US Food and Drug Administration.

Biogen wants approval of Tysabri for Crohn's disease Triangle Business Journal Fri, 15 Dec 2006 10:21 AM PST Tysabri is turning out to be a drug with multiple lives.

Elan, Biogen Idec Submit Tysabri for Crohn's RedNova Fri, 15 Dec 2006 10:08 AM PST Elan and Biogen Idec have submitted a biologics license application to the FDA seeking approval to market Tysabri in the US as a treatment for Crohn's disease.

Biogen Idec asks FDA OK for Tysabri use in Crohn's disease BizJournals Fri, 15 Dec 2006 8:15 AM PST Biogen Idec Inc. of Cambridge and its strategic partner Elan Corp. of Ireland have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for a new use of the storied drug Tysabri.

Pharmos Completes Preclinical Toxicology And Safety Pharmacology Studies In Oral Cannabinor Medical News Today Fri, 15 Dec 2006 0:13 AM PST Pharmos Corp. (Nasdaq: PARS) today announced the completion of preclinical toxicology and safety pharmacology studies of an oral formulation of cannabinor, a synthetic CB2-selective agonist, to support dosing in humans. The toxicology studies included maximum tolerated dose (MTD) studies, a 28-day repeat-dose study, and a cardiovascular safety study in animals. [click link for full article]

Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a ...
Business Wire via Yahoo! Finance Fri, 15 Dec 2006 6:10 AM PST
DUBLIN, Ireland & CAMBRIDGE, Mass.----Elan Corporation, plc and Biogen Idec announced today the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval to market TYSABRI® in the U.S. as a treatment for patients with moderately to severely active Crohn's disease .

---

Cost v quality of life
The Herald - Glasgow,Scotland,UK
... One drug, Tysabri, has been licensed for use in Britain, the United States and Europe which has been proved to be effective in alleviating the impact of some ...

Dublin market roars further above 9,000
RTE.ie - Ireland
... Elan gained 31 cent to €10.81 after saying it had asked US regulators to approve use of its MS drug Tysabri to treat Crohn's disease. ...